SavedAdd your journal

Journals / Journal of Basic and Clinical Health Sciences / 2023 / Cilt: 7 - Sayı: 1

More Abundant Superoxide Dismutase2 Protein Levels in Blood May Act as a Prognostic Marker for High-Risk Neuroblastoma Patients

Ayse Banu DEMİR
Zekiye ALTUN
Safiye AKTAŞ
Nur OLGUN
Pages
196–213
Publication Date
2023-01-31
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: SOD2 may play an important role in neuroblastoma progression and be a candidate prognostic peripheral blood marker for neuroblastoma patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: Determination of proteomic differences plays an important role in biomarker investigations.
📊
Key Findings & Data:Real-time PCR analysis were performed for N-MYC, 11q, 1p and 17q status of these patients and risk groups were determined from tumor samples.
💡
Conclusion & Impact:Conclusion: SOD2 may play an important role in neuroblastoma progression and be a candidate prognostic peripheral blood marker for neuroblastoma patients.
🔬Design:Lab & Field Experiment
📍Scope:Comprehensive Sample
⚙️Variables:Neuroblastoma · SOD2 · Risk-classification

Abstract

Purpose: Determination of proteomic differences plays an important role in biomarker investigations. Due to its heterogenic molecular background, identification of certain biomarkers is still a demand both for diagnosis and for prognosis of neuroblastoma. In this study, it is aimed to identify some marker proteins/mechanisms that may play role in neuroblastoma prognosis. Methods: A proteomic approach was performed for different risk groups of the disease by using matrix-assisted laser desorption ionization–time of flight (MALDI-TOF/TOF) approach. Mononuclear cell pools from blood samples of patients for risk groups were constructed and protein expression changes for different groups were identified. Real-time PCR analysis were performed for N-MYC, 11q, 1p and 17q status of these patients and risk groups were determined from tumor samples. Results: Manganese-superoxide dismutase (SOD2) protein was significantly increased in high-risk group of neuroblastoma patients. Conclusion: SOD2 may play an important role in neuroblastoma progression and be a candidate prognostic peripheral blood marker for neuroblastoma patients.

🔖

Cite This Article

DEMİR, A. B., ALTUN, Z., AKTAŞ, S., OLGUN, N. (2023). More Abundant Superoxide Dismutase2 Protein Levels in Blood May Act as a Prognostic Marker for High-Risk Neuroblastoma Patients. Journal of Basic and Clinical Health Sciences, Cilt: 7 - Sayı: 1, 196–213. https://ajindex.com/articles/879821

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Maris JM, Matthay KK. Molecular biology of neuroblastoma. J Clin Oncol 1999; 17: 22642279
  2. Olgun N, Kansoy S, Aksoylar S, Cetingul N, Vergin C, Oniz H, et al. Experience of the Izmir Pediatric Oncology Group on Neuroblastoma: IPOG-NBL-92 Protocol. Pediatr Hematol Oncol. 2003; 20(3):211-18
  3. Li C, Wu Z, Liu M, Pazgier M, Lu W. Chemically synthesized human surviving does not inhibit caspase-3. Protein Sci. 2008; 17(9):1624-29
  4. Berthold F. Neuroblastoma-90 (NB-90) protocol. German Pediatric Oncology Group (GPOG-NBL) 1990
  5. Matthey KK, Perez C, Seeger RC, Brodeur GM, Shimada H, Atkinson JB, et al. Successful treatment of stage III neuroblastoma based on prospective biologic staging: A Children’s Cancer Group study. J. Clin Oncol. 1998; 16:1256
  6. Krona C, Ejeskär K, Abel F, Kogner P, Bjelke J, Björk E, et al. Screening for gene mutations in a 500 kb neuroblastoma tumor suppressor candidate region in chromosome 1p; mutation and stage-specific expression in UBE4B/UFD2. Oncogene. 2003:2343-51
  7. De Preter K, Vandesompele J, Menten B, Carr P, Fiegler H, Edsjö A, et al. Positional and functional mapping of a neuroblastoma differentiation gene on chromosome 11. BMC Genomics. 2005; 6:97
  8. Wang Q, Diskin S, Rappaport E, Attiyeh E, Mosse Y, Shue D, et al. Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res. 2006; 66(12):6050-6062
  9. Souzaki R, Tajiri T, Higashi M, Kinoshita Y, Tanaka S, Kohashi K et al. Clinical implications of a slight increase in the gene dosage of MYCN in neuroblastoma determined using quantitative PCR. Pediart Surg Int. 2008; 24: 1095-1100
  10. Spitz R, Hero B, Ernestus K, Berthold F. FISH analyses for alterations in chromosomes 1,2,3, and 11 define high-risk groups in neuroblastoma, Med Pediatr Oncol. 2003; 41:30-35
  11. Shimada H, Chatten J, Newton WA Jr, Sachs N, Hamoudi AB, Chiba T, et al. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst. 1984; 73(2):405-416
  12. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP et al. Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. J Clin Oncol. 1993; 11(8):1466-1477
  13. Brodeur GM, Seeger RC, Barrett A, Castleberry RP, D'Angio G, De Bernardi B, et al. International c